JIA patients with high disease activity are characterized by higher serum levels of both neopterin and kynurenine, and a higher ratio of both KYN/TRP and PHE/TYR and lower tryptophan serum levels than in clinically inactive JIA patients, reflecting increased activity of both IDO and GTP–CH1 pathways but decreased BH4 efficacy during chronic inflammation. The gene discussed is SUCO; the disease is juvenile idiopathic arthritis.